OTC Bulletin Board S & P Company Insight for QUANTRX BIOMEDICAL
Profile
	Business Summary: QuantRx Biomedical Corporation, a diagnostics company, focuses on the development and commercialization of diagnostic products based on its patented technology platforms for the worldwide healthcare industry.   Address   100 S Main St Ste 300   Doylestown , PA 18901-4882   Phone: 267-880-1595   Fax: 267-880-1596   Website: http://www.quantrx.com Auditor   Williams & Webster Transfer Agent   Computershare Trust Co., Inc. Employees:  12 ShareHolders:  264 Founded:  1986 Domicile:  Nevada
Background
	QuantRx Biomedical Corporation, a diagnostics company, focuses on the development and commercialization of diagnostic products based on its patented technology platforms for the worldwide healthcare industry. The company's technology portfolio includes RapidSense and Q-Reader point-of-care testing products based on its core intellectual property related to lateral flow methods, devices, and processes for the consumer and healthcare professional markets; and PAD products based on its technology for aiding the treatment of hemorrhoids, vaginal infection, urinary incontinence, and other medical needs, including diagnostic sampling products. It also develops genome-based diagnostic chips for the laboratory and healthcare professional markets; and molecular imaging agents for positron emission tomography and fluorescence imaging, with initial application in cardiovascular disease that addresses unmet medical needs by providing clinicians with tools for early discovery and assessment. QuantRx Biomedical Corporation was incorporated in 1986 and is headquartered in Doylestown, Pennsylvania. History:  INCORPORATED in Nevada Dec. 9, 1986, as Xtramedics, Inc.; name changed to Athena Medical Corp. June 7, 1994, to A-Fem Medical Corp. July 17, 1997, and to QuantRx Biomedical Corp. Dec. 2, 2005.     Capital Expenditures, thousand. US Dollars   Year   Amount   2009   28   2008   74   2007   219   Research and Development Expenditures, thousand. US Dollars   Year   Amount   2009   2,324   2008   2,033   2007   2,012
Management
	Management Officers Position  Walter  Witoshkin Chairman, President & Chief Executive Officer  Sasha  Afanassiev Treasurer, Chief Financial Officer & Investor Relations Contact  William H. Fleming Secretary & Chief Scientific Officer  Martin  Harvey Controller Directors  William H. Fleming  Shalom Z. Hirschman  Patrick T. Mooney  Robert G. Pinco  Walter  Witoshkin
Annual Report
	Annual Report   Income Statement   2009 2008 REVENUES Revenues, Related Party 2,065,264 - Revenues 486,005 624,495 Total Revenues 2,551,269 624,495 EXPENSES Cost of Goods Sold (27,853) (61,896) Professional Fees (497,582) (957,135) Selling and Marketing Expenses (10,118) (94,603) General and Administrative (2,002,964) (2,894,432) Research and Development (2,324,286) (2,032,677) Depreciation and Amortization (70,082) (103,992) Amortization (22,402) (179,444) Interest Expense (465,027) (369,895) Amortization of Deferred Financing Costs to Interest Expense (8,693) (309,164) Amortization of Debt Discount to Interest Expense (361,666) (1,148,512) Interest and Dividend Income 40,095 22,622 Loss from Joint Venture (1,022,760) - Loss on Extinguishments of Debt - (439,445) Rental Income 20,798 23,373 Gain/loss on Disposition of Assets 1,363,640 (8,029) Loss from Deconsolidated Subsidiary (272,579) - Loss from Deconsolidation of Subsidiary (43,286) - Earnings before Taxes (3,153,496) (7,928,734) TAXES AND OTHER EXPENSES Minority Interest (After Tax) - 207,333 Net Income (Loss) (3,153,496) (7,721,401) SUPPLEMENTARY INFO Operating Income (Loss) (2,404,018.00) (5,699,684.00) Basic EPS - Continuing Operations (0.07) (0.18)   Balance Sheet   2009 2008 CURRENT ASSETS Cash and Cash Equivalents 376,211 66,226 Deposits - 104,146 Accounts Receivable, Related Party 31,500 - Accounts Receivable Trade 41,128 45,760 Interest Receivable, Related Party 47,689 31,689 Notes Receivable-related Party 200,000 200,000 Inventories 4,681 40,138 Deferred Finance Costs-(Net) - 8,693 Prepaid Expenses 128,228 189,049 Total Current Assets 829,437 685,701 NON CURRENT ASSETS Fixed Assets-net 179,590 496,206 Investment in Joint Venture 63,601 - Investments 200,000 200,000 Intangible Assets, Net 59,780 2,012,097 Security Deposit 11,093 10,667 Total Assets 1,343,501 3,404,671 CURRENT LIABILITIES Accounts Payable 749,225 2,205,661 Accrued Expenses 233,000 298,692 Short-term Secured Promissory Notes Payable - 350,000 Short-term Convertible Notes Payable, Net of Discount - 2,510,054 Short-term Promissory Notes Payable, Net of Discount - 1,061,278 Loan Payable - 5,731 Deferred Revenue-related Party 337,160 - Deferred Revenue - 58,781 Security Deposit 2,000 2,000 Total Current Liabilities 1,321,385 6,492,197 NON CURRENT LIABILITIES Notes Payable-long-term 44,000 44,000 Preferred Stock Convertible 40,604 - SHAREHOLDERS' EQUITY Common Stock - Par Value 444,276 428,863 Additional Paid in Capital 47,756,360 41,549,230 Accumulated Deficit (48,263,120) (45,109,620) Total Shareholders Equity (21,884) (3,131,526) Total Liabilities & Shareholders Equity 1,343,501 3,404,671
Interim Report
	Interim Report      Data Not Available
Pro Forma Report
	Pro Forma Report      Data Not Available
Quarterly Report
	Quarterly Report Information      Quarterly Revenue, US$ Year Quarter Revenue   2010   1 660,000   2009   1 160,000   2009   2 170,000   2009   3 990,000   2009   4 1,230,000   2009   Full Year 2,550,000   2008   1 90,000   2008   2 160,000   2008   3 220,000   2008   4 150,000   2008   Full Year 620,000   2007   1 60,000   2007   2 110,000   2007   3 90,000   2007   4 490,000   2007   Full Year 750,000   2006   1 10,000   2006   2 10,000   2006   3 30,000   2006   4 40,000   2006   Full Year 90,000   2005   1 10,000   2005   2 10,000   2005   3 10,000   2005   4 20,000   2005   Full Year 60,000     Quarterly Net Income, US$ Year Quarter Revenue   2010   1 (330,000)   2009   1 (1,140,000)   2009   2 (750,000)   2009   3 (250,000)   2009   4 (1,010,000)   2009   Full Year (3,150,000)   2008   1 (2,020,000)   2008   2 (2,140,000)   2008   3 (2,070,000)   2008   4 (1,500,000)   2008   Full Year (7,720,000)   2007   1 (1,040,000)   2007   2 (2,430,000)   2007   3 (1,330,000)   2007   4 (1,250,000)   2007   Full Year (6,040,000)   2006   1 (1,560,000)   2006   2 (2,030,000)   2006   3 (1,960,000)   2006   4 (2,140,000)   2006   Full Year (7,693,000)   2005   Full Year (1,093,000)     Quarterly EPS, US$ Year Quarter Revenue   2010   1 (.01)   2009   1 (.03)   2009   2 (.02)   2009   3 (.01)   2009   4 (.02)   2009   Full Year (.07)   2008   1 (.05)   2008   2 (.05)   2008   3 (.05)   2008   4 (.03)   2008   Full Year (.18)   2007   1 (.05)   2007   2 (.06)   2007   3 (.03)   2007   4 (.03)   2007   Full Year (.15)   2006   1 (.06)   2006   2 (.07)   2006   3 (.06)   2006   4 (.07)   2006   Full Year (.26)   2005   1 Nil   2005   2 (.01)   2005   3 (.03)   2005   4 (.02)   2005   Full Year (.07)
Stock Data
	Capitalization as of 03/31/2010:     Authorized Shares Outstanding Shares Preferred $0.01 par 25,000,000 4,060,397so1 Common $0.01 par 150,000,000 44,427,630   LONG TERM DEBT: $44,000.   Common $0.01 par   Stockholders:  03/22/2010, 264. Transfer Agent:  Computershare Trust Co., Inc.   Golden , CO   OTC Bulletin Board( Primary): QTXB   Exchange Year High Low OTC Bulletin Board 2009 0.5900 0.1800 OTC Bulletin Board 2008 1.1100 0.2000 OTC Bulletin Board 2007 1.6000 0.4300 OTC Bulletin Board 2006 1.6900 0.9500 Over The Counter 2005 2.0000 0.2500 Over The Counter 2004 0.7550 0.0001   DIVIDENDS: Common $0.01 par: No cash.       so1Closely held. Consists of Series A-1 shares, each of which is convertible into 2 Common shares.